Hemispherx BioPharma, Inc. (NYSEMKT:HEB)

CAPS Rating: 1 out of 5

A biopharmaceutical company engaged in the clinical development, manufacture, marketing and distribution of new drug entities based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders.

Results 1 - 20 of 37 : 1 2 Next »

Recs

2
Member Avatar zzlangerhans (99.69) Submitted: 1/23/2014 7:07:44 PM : Outperform Start Price: $0.53 HEB Score: -57.08

As far back as October, some traders were musing on Twitter on the large number of junk biopharma companies making huge upward moves. Someone stated "when the very last of the junk have these moves, that when we know its over for a while." I replied "That would be $HEB. Who's ready to go long?"

Come January, the number of junk biopharmas whose share price has at least doubled has more than doubled. And Hemispherx, whose share price was about 22 cents when I wrote that Tweet, closed at 56 cents today. Too bad I didn't put my money where my mouth was, but as usual market irrationality exceeded even my wildest speculation. Of all the biopharmas I follow, I consider Hemispherx to have the lowest probability for drug approval or commercial success. Lower than Cellceutix, lower than Star Scientific, lower than Pluristem. Nevertheless, Hemispherx will never die as long as traders enjoy using it as a blackjack table. These days, the stock seems to be rising as management heats up their case for treatment of pandemic flu with Alferon, their proprietary formulation of interferon alpha. Hemispherx has been playing up this angle for months, but as the biopharma sector has gotten frothier the tone and frequency of their press releases has become shriller. At last, it seems to be working.

I've decided to change up my usual M.O. and go with momentum on Hemispherx for now. After all, there's really no rationality out there to stop the share price from going to 5 - just look at Prana and Oxygen Bio, for a couple of examples. That means there's a lot more upside than downside from a green thumb close to the 0.5 threshold.

Recs

1
Member Avatar BioPharmacist (< 20) Submitted: 12/12/2012 1:48:29 AM : Outperform Start Price: $0.70 HEB Score: -98.81

Gonna surprise everyone with an advisory committee panel that votes in favor of accelerated approval with phase 4 trials being required.

Recs

0
Member Avatar Amagi (99.77) Submitted: 10/31/2012 7:17:19 PM : Underperform Start Price: $0.83 HEB Score: +107.11

Shorting what the pumpers say to buy.

Recs

0
Member Avatar SnarkyApple (41.35) Submitted: 9/18/2012 12:51:34 PM : Underperform Start Price: $0.80 HEB Score: +101.24

Shenanigans.

Recs

0
Member Avatar mrcarlen (< 20) Submitted: 11/17/2010 7:44:41 PM : Underperform Start Price: $0.51 HEB Score: +112.81

Projections don't look good

Recs

1
Member Avatar Displacement (< 20) Submitted: 9/28/2009 3:20:59 PM : Outperform Start Price: $2.05 HEB Score: -173.06

Will this be big in a year? Nahh. Will this be big in a couple months when the FDA pushes through the H1N1 kit? Sure. Riding it short term because there's decent support at 2 and it might get another launch before it sputters out.

Recs

0
Member Avatar Thelmal (48.81) Submitted: 9/25/2009 9:30:32 AM : Outperform Start Price: $2.00 HEB Score: -175.49

safe bet

Recs

0
Member Avatar AbeNebo (< 20) Submitted: 9/1/2009 12:21:23 AM : Outperform Start Price: $2.37 HEB Score: -183.58

If FDA Approve.

Recs

0
Member Avatar redwings103149 (< 20) Submitted: 8/24/2009 6:09:10 PM : Outperform Start Price: $2.14 HEB Score: -179.42

Under heavy accumulation by barclays and other major players who know alot more than we do. Time to jump on baby

Recs

0
Member Avatar BustaCAPS (< 20) Submitted: 8/14/2009 10:56:37 AM : Underperform Start Price: $1.97 HEB Score: +185.00

UltraLong play

Recs

0
Member Avatar Brian7992 (57.31) Submitted: 8/11/2009 2:29:09 PM : Outperform Start Price: $1.99 HEB Score: -185.33

Love this one

Recs

0
Member Avatar Slam54 (< 20) Submitted: 7/10/2009 1:21:22 AM : Outperform Start Price: $2.22 HEB Score: -214.37

Pending FDA approval

Recs

0
Member Avatar Siforus (< 20) Submitted: 6/25/2009 8:27:28 PM : Outperform Start Price: $2.36 HEB Score: -205.10

Ampligen will be approved.
The Swiss have their hands all in this stuff!

Recs

1
Member Avatar scrxdagain (< 20) Submitted: 6/24/2009 3:57:51 PM : Outperform Start Price: $1.89 HEB Score: -207.37

Despite a dubious history for Ampligen, and some sloppy business moves, the drug will be approved. Once that happens, the likelihood of approval for a second orphan drug increases dramatically.

Recs

0
Member Avatar marginaddict (< 20) Submitted: 6/22/2009 10:51:28 PM : Underperform Start Price: $2.13 HEB Score: +209.42

Snake oil.

Recs

0
Member Avatar prcltrader (79.00) Submitted: 6/19/2009 11:39:49 AM : Outperform Start Price: $2.46 HEB Score: -205.13

Waiting on FDA approval for Ampligen.

Recs

0
Member Avatar kropopkin (44.78) Submitted: 6/11/2009 7:16:39 AM : Underperform Start Price: $2.52 HEB Score: +200.56

There is so much pumping on little hard evidence, and a lot of smoke and mirrors being used here. Also, a large boost to the price based on the swine flu adjuvant aspect, where as it seems lost on the masses that possible FDA approval is for CFS and not a vaccination adjuvant.

Possible that it all comes together, but I wouldn't be putting my money into this murky waters at the moment.

Recs

0
Member Avatar jjupita (< 20) Submitted: 6/5/2009 5:15:13 PM : Outperform Start Price: $2.99 HEB Score: -203.87

Normally when investing in a company, I consider recommendations, then I evaluate fundamentals, and finally I make an emotional decision.

I admit that HEB is not backed by fundamentals, so I'm breaking my own rule. It's trading on hype (read: fun), and is therefore purely speculative. That's why I've only got disposable cash behind it right now.

But consider the following - there are no FDA approved drugs on the market for Chronic Fatigue Syndrome. It will need to be treated somehow, someway. Anybody else working on a solution?

Perhaps more buzzworthy is all the H1N1/H5N1 discussion. Everyone is racing for a cure. Japan - where normal people where face masks in public - thinks HEB is most likely to have it.

Consider lastly the decidedly negative articles written time and time again by Adam Feuerstein. I can't help but question his journalistic ethics - someone, if not him, stands to gain whenever his missives shrink the stock. He claims that HEB's CEO is maniuplating the news to benefit the stock price. There's a novel idea, a CEO who wants his stock price to GO UP! Of course he does - that's what CEO's of company DO! So I have to wonder, why does Feuerstein want the stock to go down? I'm hoping it's so he can buy shares cheaper!!! Guess we can all thank him for the temporary discount.

All in, I think the upside is worth the risk. No Ampligen FDA approval and no deals with Japan means $2.50/share going back to $.25 pretty quickly - sucks, I admit. But $2.50 going to $10 is a vacation to someplace tropical.

See you on the beach!

Recs

0
Member Avatar dudefucker (< 20) Submitted: 6/4/2009 11:03:35 PM : Underperform Start Price: $4.09 HEB Score: +202.52

This stock is overpriced. Even if FDA approves, how far do you think this stock price would climb?

Recs

1
Member Avatar giggy63 (< 20) Submitted: 5/30/2009 12:20:22 PM : Outperform Start Price: $1.75 HEB Score: -197.98

Ampligen will be approved.

Results 1 - 20 of 37 : 1 2 Next »

Featured Broker Partners


Advertisement